These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20388724)

  • 41. Tuberculosis in Europe: a problem of drug resistance or much more?
    Carvalho AC; Migliori GB; Cirillo DM
    Expert Rev Respir Med; 2010 Apr; 4(2):189-200. PubMed ID: 20406085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MDR-TB and XDR-TB: drug resistance and treatment outcomes.
    Migliori GB; Sotgiu G; D'Arcy Richardson M; Centis R; Facchini A; Guenther G; Spanevello A; Lange C;
    Eur Respir J; 2009 Sep; 34(3):778-9. PubMed ID: 19720816
    [No Abstract]   [Full Text] [Related]  

  • 43. Common errors in multidrug-resistant tuberculosis management.
    Monedero I; Caminero JA
    Expert Rev Respir Med; 2014 Feb; 8(1):15-23. PubMed ID: 24329041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TIMEBOMB revisited 10 years later: can we sustain progress or are we losing the war?
    Reichman LB
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1377-82. PubMed ID: 24125437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Caring for children with drug-resistant tuberculosis: practice-based recommendations.
    Seddon JA; Furin JJ; Gale M; Del Castillo Barrientos H; Hurtado RM; Amanullah F; Ford N; Starke JR; Schaaf HS;
    Am J Respir Crit Care Med; 2012 Nov; 186(10):953-64. PubMed ID: 22983960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personalized medicine for patients with MDR-TB.
    Olaru ID; Lange C; Heyckendorf J
    J Antimicrob Chemother; 2016 Apr; 71(4):852-5. PubMed ID: 26507429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of multidrug-resistant tuberculosis and patients in retreatment.
    Caminero JA
    Eur Respir J; 2005 May; 25(5):928-36. PubMed ID: 15863653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The paradigm shift to end tuberculosis. Are we ready to assume the changes?
    Monedero I; Bhavaraju R; Mendoza-Ticona A; Sánchez-Montalvá A
    Expert Rev Respir Med; 2017 Jul; 11(7):565-579. PubMed ID: 28562103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)].
    Schaberg T; Otto-Knapp R; Bauer T
    Pneumologie; 2015 May; 69(5):282-6. PubMed ID: 25970122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methods for selecting regimen duration to prevent relapse in drug-susceptible and drug-resistant TB.
    Davies GR; Wallis RS
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):13-17. PubMed ID: 28240567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive clinical trials in tuberculosis: applications, challenges and solutions.
    Davies GR; Phillips PP; Jaki T
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):626-34. PubMed ID: 25946350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytokine therapy of tuberculosis at the crossroads.
    Reljic R; Paul MJ; Arias MA
    Expert Rev Respir Med; 2009 Feb; 3(1):53-66. PubMed ID: 20477282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antituberculosis therapy for 2012 and beyond.
    Lauzardo M; Peloquin CA
    Expert Opin Pharmacother; 2012 Mar; 13(4):511-26. PubMed ID: 22332895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection and treatment of multidrug resistant TB in India remains low.
    Travasso C
    BMJ; 2013 Sep; 347():f5414. PubMed ID: 24002869
    [No Abstract]   [Full Text] [Related]  

  • 55. [The New WHO Guidelines for Rapid Diagnostics and Treatment of Drug-Resistant Tuberculosis Commented for Germany, Austria and Switzerland].
    Otto-Knapp R; Knappik M; Häcker B; Starzacher K; Bauer T; Lange C; Maurer FP; Schaberg T; Günther G
    Pneumologie; 2020 Nov; 74(11):742-749. PubMed ID: 33202437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance-based technical support for drug-resistant TB responses: lessons from the Green Light Committee.
    Yassin MA; Samson K; Wandwalo E; Grzemska M; Gegia M; Nwaneri N; Hansen P; Kunii O
    Int J Tuberc Lung Dis; 2020 Jan; 24(1):22-27. PubMed ID: 32005303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oldie but goodie: Repurposing penicillin for tuberculosis.
    Keener AB
    Nat Med; 2014 Sep; 20(9):976-8. PubMed ID: 25198041
    [No Abstract]   [Full Text] [Related]  

  • 58. Despite being a dim memory in some parts of the world, TB grinds on in many low and middle income countries.
    Tarafdar SS
    BMJ; 2019 Dec; 367():l7050. PubMed ID: 31888869
    [No Abstract]   [Full Text] [Related]  

  • 59. A Disease's Journey: Tools used to reconstruct the rise of drug-resistant tuberculosis could also be applied in real time to ward off would-be epidemics.
    Nuwer R
    Sci Am; 2020 Feb; 322(2):19. PubMed ID: 39026406
    [No Abstract]   [Full Text] [Related]  

  • 60. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.
    Akalu TY; Clements ACA; Wolde HF; Alene KA
    Sci Rep; 2023 Dec; 13(1):22361. PubMed ID: 38102144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.